Use of Antihypertensive Medications and Survival of Breast, Colorectal, Lung, or Stomach Cancer.

Use of Antihypertensive Medications and Survival of Breast, Colorectal, Lung, or Stomach Cancer. Am J Epidemiol. 2019 May 07;: Authors: Cui Y, Wen W, Zheng T, Li H, Gao YT, Cai H, You M, Gao J, Yang G, Zheng W, Xiang YB, Shu XO Abstract Influence of antihypertensive medications on cancer survival is inconclusive. Using time-dependent Cox regression models, we examined associations of common antihypertensive medications with overall survival (OS) and disease-specific survival (DSS) with comprehensive adjustment for potential confounding factors. Participants were from the Shanghai Women's Health Study (SWHS; 1996-2000) and Shanghai Men's Health Study (SMHS; 2002-2006) in Shanghai, China. Included were 2,891 incident breast, colorectal, lung, and stomach cancer cases. Medication use was extracted from electronic medical records. Median 3.4 year post-diagnosis follow-up (interquartile range=1.0-6.3) found better outcomes among users of angiotensin II receptor blockers with colorectal cancer (OS: adjusted HR=0.62, 95%CI: 0.44, 0.86; DSS: adjusted HR=0.61, 95%CI: 0.43, 0.87) and stomach cancer (OS: adjusted HR=0.62, 95%CI: 0.41, 94; DSS: adjusted HR=0.63, 95%CI: 0.41, 98) and among users of beta-adrenergic receptor blockers with colorectal cancer (OS: adjusted HR=0.50, 95%CI: 0.35, 0.72; DSS: adjusted HR=0.50, 95%CI: 0.34, 0.73). Better survival was also found for calcium channel blockers (DSS: adjusted HR=0.67, 95%CI: 0.47, 97) and diure...
Source: Am J Epidemiol - Category: Epidemiology Authors: Tags: Am J Epidemiol Source Type: research